JeffreySHeierMD

Ophthalmology • Boston, MA

Retinal Disease

Assistant Professor, Ophthalmology, Tufts Medical Center

Join to view full profile

Dr. Heier is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Heier's full profile

Already have an account?

Office
50 Staniford St
Ste 600
Boston, MA 02114
Phone+1 617-367-4800

Fax+1 617-723-7028

Education & Training

Fitzsimons Army Medical CenterResidency, Ophthalmology, 1991 - 1994
Fitzsimons Army Medical CenterInternship, Transitional Year, 1989 - 1990
Boston University School of MedicineClass of 1989

Certifications & Licensure

MA State Medical License 1996 - 2026
RI State Medical License 1998 - 2004
PA State Medical License 1993 - 1998
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Super Doctor SuperDoctors.com
Fellow (FAAO) American Academy of Ophthalmology
Join now to see all

Clinical Trials

Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration. Start of enrollment: 2005 Dec 01
Completed
Phase 1
Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser Start of enrollment: 2007 Jun 01
Unknown status
Phase 1
A Study to Evaluate the Neovista Ophthalmic System for the Treatment of Subfoveal CNV in Patients With AMD That Have Failed Primary Anti-VEGF Therapy Start of enrollment: 2007 Dec 01
Completed
Phase 2
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration Start of enrollment: 2010 Jun 01
Completed
Phase 1
A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment Start of enrollment: 2013 Oct 01
Completed
Phase 1
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA Start of enrollment: 2014 Aug 01
Completed
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO) Start of enrollment: 2017 Apr 01
Completed
Phase 2
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Start of enrollment: 2019 Nov 15
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Gene therapy for AMD: better as an adjuvant than a replacement - Authors' reply.
Peter A Campochiaro, Robert L Avery, David M Brown, Jeffrey S Heier, Sherri Van Everen
Lancet. 2025-03-08
1 citations
MERLIN: Two-Year Results of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
David M Brown, Glenn J Jaffe, Charles C Wykoff, Eser Adiguzel, Jeffrey S Heier
Ophthalmology. 2025-02-01
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies.
Jeffrey S Heier, Eleonora M Lad, Frank G Holz, Philip J Rosenfeld, Robyn H Guymer
Immunotherapy. 2025-01-17

Press Mentions

Tips for Going Solo During a PandemicMarch 25th, 2022
Trials Show Promise for Intravitreal Faricimab in Retinal DiseaseFebruary 2nd, 2022
2020 on-Site Forms Industry and Scientific Advisory BoardJune 23rd, 2021
Join now to see all

Professional Memberships

American Academy of Ophthalmology - AAO
Fellow